ReviewThe Journal of clinical endocrinology and metabolism2016
Pituitary Medicine From Discovery to Patient-Focused Outcomes.
Review in The Journal of clinical endocrinology and metabolism, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Risk factors for tumor recurrence and progression of spindle cell oncocytoma of the pituitary gland: a systematic review and pooled analysis.Pituitary · 2021Pooled it
- Approach to the patient: precision medicine-guided evaluation and treatment of acromegaly.The Journal of clinical endocrinology and metabolism · 2026Review
- Cost-effectiveness of personalized medical treatment in acromegaly: a post hoc analysis of the ACROFAST study.Journal of the Endocrine Society · 2026Article
- Severe hyponatremia as an atypical manifestation of pituitary macroadenoma: a case report.Annals of medicine and surgery (2012) · 2023Article
- Clinical Biology of the Pituitary Adenoma.Endocrine reviews · 2022Review
- Is prolactin receptor signaling a target in dopamine-resistant prolactinomas?Frontiers in endocrinology · 2022Review
- Molecular targets in acromegaly.Frontiers in endocrinology · 2022Review
- Hypothalamic-Pituitary Autoimmunity in Patients Treated with Anti-PD-1 and Anti-PD-L1 Antibodies.Cancers · 2021Article
- Autophagy in normal pituitary and pituitary tumor cells and its potential role in the actions of somatostatin receptor ligands in acromegaly.Reviews in endocrine & metabolic disorders · 2021Review
- Multidisciplinary Team Care in the Surgical Management of Pituitary Adenoma.Journal of neurological surgery. Part B, Skull base · 2021Article
- The GALANT trial: study protocol of a randomised placebo-controlled trial in patients with aBMJ open · 2020Article
- Review
- Non-functioning pituitary adenomas: indications for pituitary surgery and post-surgical management.Pituitary · 2019Review
- Clinical usefulness of 99mTc-HYNIC-TOC, 99mTc(V)-DMSA, and 99mTc-MIBI SPECT in the evaluation of pituitary adenomas.Nuclear medicine communications · 2019Article
- International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature.Pharmacological reviews · 2018Review
- A Consensus Statement on acromegaly therapeutic outcomes.Nature reviews. Endocrinology · 2018Review
- Silent somatotroph pituitary adenomas: an update.Pituitary · 2018Review
- Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database.Endocrine-related cancer · 2017Article
- Melvin M. Grumbach 1925-2016.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Pathology of GH-producing pituitary adenomas and GH cell hyperplasia of the pituitary.Pituitary · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
contextThis perspective traces a pipeline of discovery in pituitary medicine over the past 75 years.
objectiveTo place in context past advances and predict future changes in understanding pituitary pathophysiology and clinical care.
designAuthor's perspective on reports of pituitary advances in the published literature.
settingClinical and translational Endocrinology. OUTCOMES: Discovery of the hypothalamic-pituitary axis and mechanisms for pituitary control, have culminated in exquisite understanding of anterior pituitary cell function and dysfunction. Challenges facing the discipline include fundamental understanding of pituitary adenoma pathogenesis leading to more effective treatments of inexorably growing and debilitating hormone secreting pituitary tumors as well as medical management of non-secreting pituitary adenomas. Newly emerging pituitary syndromes include those associated with immune-targeted cancer therapies and head trauma.
conclusionsNovel diagnostic techniques including imaging genomic, proteomic, and biochemical analyses will yield further knowledge to enable diagnosis of heretofore cryptic syndromes, as well as sub classifications of pituitary syndromes for personalized treatment approaches. Cost effective personalized approaches to precision therapy must demonstrate value, and will be empowered by multidisciplinary approaches to integrating complex subcellular information to identify therapeutic targets for enabling maximal outcomes. These goals will be challenging to attain given the rarity of pituitary disorders and the difficulty in conducting appropriately powered prospective trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.